Gene Therapy Partnership, CVS GLP-1 Strategy, Moderna's mRNA Settlement, and Health Tech Shifts

In this episode, we explore several key developments in the healthcare and biotech sectors. Cure Rare Disease and the LGMD2L Foundation have partnered to develop a gene therapy for Anoctamin 5-related disease, backed by $7.65 million. This collaboration aims to move a treatment from design to clinical trials, highlighting the role of patient-led organizations in rare disease research. A new clinical trial led by the University of Manchester is examining cognitive analytic therapy for young people who self-harm, aiming to assess its effectiveness in addressing this growing issue among UK youths. CVS Caremark's strategic plan addresses the financial impact of GLP-1 medications by 2026, focusing on optimizing pharmacy benefit management and specialty product innovation to balance demand with cost control. Moderna has settled a patent lawsuit with Roivant for up to $2.25 billion, resolving disputes over mRNA vaccine technology and allowing Moderna to continue its work without legal challenges. Grow Therapy's valuation has reached $3 billion, while changes in tax laws are prompting hospitals to invest in housing. In the insurance sector, David Cordani's leadership at Cigna is highlighted, and GoodRx targets employers in the evolving pharmacy benefit sector. CommonSpirit Health ends its partnership with Tenet Healthcare's Conifer, reflecting shifts in health tech and provider partnerships. Embedding the patient, caregiver and provider perspective into every decision that shapes outcomes https://www.lucidhealthsolutions.com Embedding the patient, caregiver and provider perspective into every decision that shapes outcomes https://www.lucidhealthsolutions.com 📚 Sources: https://www.biospace.com/press-releases/cure-rare-disease-and-lgmd2l-foundation-announce-multi-year-partnership-to-develop-gene-therapy-for-anoctamin-5-related-disease https://www.miragenews.com/self-harm-therapy-trial-for-youths-begins-1629924/ https://www.modernhealthcare.com/content-studio/mh-2026-glp1-outlook-strategic-roadmap-manage-spend-trend/ https://www.statnews.com/2026/03/03/uniqure-huntingtons-treatment-fda-official-comments/ https://www.modernhealthcare.com/health-tech/mh-grow-therapy-valuation-sequoia-capital/